1. PD-015Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies. (2nd July 2019) Authors: Rossini, D; Sbrana, A; Bergamo, F; Manai, C; Santini, D; Ghidini, M; Antoniotti, C; Moretto, R; Marmorino, F; Urbano, F; Ronzoni, M; Noventa, S; Randon, G; Carlomagno, C; Latiano, T; Cordio, S; Granetto, C; Cremolini, C; Falcone, A; Antonuzzo, A Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PD-019Optimizing treatment with anti-epidermal growth factor receptor drugs for patients with metastatic colorectal cancer: novel mechanisms of resistance beyond RAS. (2nd July 2019) Authors: Cardone, C; Blauensteiner, B; Moreno-Viedma, V; Paul, M; Martini, G; Troiani, T; Vitiello, P; Ciardiello, D; Poliero, L; Borrelli, C; Rachiglio, A; Rizzi, D; Maiello, E; Latiano, T; Normanno, N; Sibilia, M; Ciardiello, F; Martinelli, E Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗